Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
Metformin is an oral antidiabetic of the biguanide class derived from galega officinalis.
Historical cohort of patients with diabetes have shown that diabetics on Metformin had a
better chance of survival than diabetics not on Metformin. These observations have led to in
vitro studies of metformin on cancer cells. It was thus demonstrated that Metformin has
anti-proliferative properties.
The aim of our study is to evaluate the efficacy of metformin in combination with neoadjuvant
radiochemotherapy in the treatment of locally advanced rectal cancer.